Navigation Links
500th Patient Receives Berlin Heart EXCOR Pediatric Ventricular Assist Device
Date:5/28/2009

BERLIN, May 28 /PRNewswire/ -- The 500th patient was supported with the Berlin Heart EXCOR(R) Pediatric Ventricular Assist Device (also known as the "Berlin Heart") since the first implantation of the device in 1990. The patient, an 11-month-old girl, received the device at the Children's Memorial Hospital in Chicago and has been successfully transplanted in the meantime.

Alejandra had been diagnosed a few weeks after birth with left ventricular non compaction and dilative cardiomyopathy, a disease that causes the heart muscle to enlarge and weaken. From six months of age, she received medications for her heart disease, but as she progressively worsened, she had to be placed on the waiting list for a donor heart. She presented to Dr. Elfriede Pahl, medical director of heart transplantation at Children's Memorial Hospital, with a respiratory infection and required mechanical ventilation.

Alejandra was placed on ECMO, a modified version of a heart-lung machine, on 2 January 2009, but rapidly deteriorated. "She was difficult to support on ECMO with a good deal of bleeding and relatively poor systemic perfusion," recalls Dr. Jeffrey Gossett, Alejandra's cardiologist. "As a result we needed to continue paralysis and were unable to feed her well."

By the time she received the Berlin Heart EXCOR Pediatric VAD, she had spent 38 days on mechanical ventilation and three days on ECMO. Alejandra's mother recalls, "We were devastated and very anxious. We had to hope for a miracle to help Alejandra."

    Full story under:
http://www.berlinheart.com/500th_EXCOR_Pediatric_Patient_full_story.pdf

Pictures available.

About EXCOR(R) Pediatric

The EXCOR Pediatric Ventricular Assist Device is a mechanical cardiac support system for critically ill pediatric patients suffering from severe heart failure. EXCOR Pediatric has been used in more than 500 pediatric patients worldwide ranging from newborns with 2.2 kg body weight to teenagers. EXCOR is currently under clinical investigation for pediatric patients in USA.

About Berlin Heart

Berlin Heart GmbH is the only company worldwide that develops, produces, and distributes implantable and external ventricular assist devices (also called mechanical heart support systems) for patients of every age and body size. The company is market leader in Germany and Europe.

The company also manufactures the implantable left ventricular assist device INCOR(R), which has been designed for long-term application in adult patients. The longest the device has supported a patient so far is more than five and a half years and ongoing. INCOR is not FDA approved, but widely used in Europe.

    Contact:

    Linda Buerk
    Manager Marketing & PR
    Phone: +49(0)30-8187-2650
    Mobile: +49(0)173-629-0803
    buerk@berlinheart.de



'/>"/>
SOURCE Berlin Heart GmbH
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Plexon Inc Delivers 500th "Harvey Box" : 25 Years of Neural Data Acquisition and Analysis Leads to 500th System Sale
2. Leaders in Health Literacy Recognized by the Partnership for Clear Health Communication at the National Patient Safety Foundation
3. SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System
4. First Use in Coronary Patients of a Combined Near-Infrared Spectroscopy and Ultrasound Imaging Catheter
5. Healthcare Leaders to Address Patient Safety and Reform at the National Patient Safety Foundation Congress, Washington, DC, May 20-22
6. VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients
7. Adipose-derived Stem Cells Could Help Traumatic Brain Injury Patients, Says Bio-Matrix Scientific Groups, Entest BioMedical Inc. Researcher
8. Boston Scientific to Donate Cardiac Rhythm Management Devices to Heartbeat International for Implantation in Needy Patients
9. Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study
10. Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB
11. Evoke Pharma, Inc. Initiates Phase 2b Metoclopramide Intranasal Trial (MINT) in Patients With Diabetic Gastroparesis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... Ca (PRWEB) , ... July 25, 2017 , ... ... specialty converted media and software solutions that enable short-run digital printing, is proud ... Chemical Labels and its free GHS Wizard online software available at avery.com/GHS ...
(Date:7/26/2017)... MA (PRWEB) , ... July 26, 2017 , ... ... a variety of complex problems we face every day. This unique capability ... researchers, agronomists, geologists, chemists, and manufacturers to deliver unprecedented datasets for chemical analysis, ...
(Date:7/25/2017)... ... July 25, 2017 , ... Fiberstar, Inc ., a global market leader ... 125. This natural citrus fiber is used to improve tomato-based food products by replacing ... condiments and spreads. Today, more than ever, consumers connect ingredients to the foods they ...
(Date:7/24/2017)... ... July 24, 2017 , ... Each year, Inavero’s ... have proven their superior service quality as rated by hiring professionals and job ... leader based on service quality ratings from their placed talent. , Fewer than ...
Breaking Biology Technology:
(Date:4/5/2017)... -- The Allen Institute for Cell Science today announces the ... and dynamic digital window into the human cell. The ... of deep learning to create predictive models of cell ... growing suite of powerful tools. The Allen Cell Explorer ... available resources created and shared by the Allen Institute ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
Breaking Biology News(10 mins):